---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-065320"
form_type: "8-K"
ticker: "KYTX"
cik: "0001994702"
company_name: "Kyverna Therapeutics, Inc."
filed_at: "2026-02-24T23:59:59+00:00"
generated_at: "2026-05-16T00:55:20.973505+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Kyverna appoints Andrew Miller and Sravan Emany to Board; Spiegelman resigns

## Summary
- Andrew Miller (Karuna founder) appointed Class III director; granted option valued at $262k and RSUs valued at $87.5k.
- Sravan Emany (Beam CFO) appointed Class I director and Audit Committee Chair; receives same initial equity awards.
- Daniel Spiegelman resigned Feb 24, no disagreement with company operations, policies or practices.
- Miller brings drug development experience from Karuna's $14B BMS acquisition; Emany adds capital markets and rare disease expertise.
- Both directors receive cash comp: $40k board retainer plus committee fees; equity vests over 3 years with full acceleration on change of control.

## SEC filing metadata
- accession: 0001193125-26-065320
- form_type: 8-K
- ticker: KYTX
- cik: 0001994702
- company_name: Kyverna Therapeutics, Inc.
- filed_at: 2026-02-24T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1994702/000119312526065320/0001193125-26-065320-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1994702/000119312526065320/kytx-20260224.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-065320
- JSON: https://secwatch.observer/filing/0001193125-26-065320.json
- Plain text: https://secwatch.observer/filing/0001193125-26-065320.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.